Patented solution technology capable of preserving and culturing any cell in the human body presents a unique opportunity to impact cellular therapy, vaccine production, regenerative medicine and organ preservation.

Our US based biotechnology company has developed a proprietary synthetic preservation solution that contains cellular nutrients and a non-animal protein oxygen and nanoparticle carrier. This highly innovative technology has been successful in preserving solid organ, heart, limbs and skin cells at room temperature, cryopreserve vaccine cells and equine stem cells without the use of DMSO and culture cancer cells and vaccine cells without the use of fetal bovine serum.

The technology is highly innovative and flexible to impact a variety of markets through cost reductions in manufacturing, FDA regulation due to animal based products and the establishment of niche markets such as limb preservation and blood substitute. Our client is seeking partners for its proprietary technology that desire to advance innovation to their respective markets.

Our client is interested in establishing a partnership for its technology in the area of organ preservation outside North America. Our client is interested in worldwide partnerships for all other potential applications in the fields of cellular therapy, vaccine production and regenerative medicine. The client will also consider an out-licensing arrangement.